NHS England to Provide Innovation and Technology Payment (ITP) to Drive
Adoption of HeartFlow Analysis in the United Kingdom
HeartFlow Analysis recognized as proven innovation to deliver efficiency
and improve quality in healthcare
REDWOOD CITY, Calif. - April 10, 2018 - HeartFlow, Inc. today announced that NHS England
has chosen the HeartFlow FFRct Analysis as part of the Innovation and Technology Payment
(ITP) program. The HeartFlow Analysis was chosen as a new technology to be funded by ITP
through a competitive process of nearly 300 applicants. It is the only ITP recipient focused on
coronary artery disease (CAD), which affects 2.3 million people in the UK.i
The goal of the ITP is to create the conditions necessary for proven innovations to be adopted
faster and more systematically throughout the NHS. Through a competitive process, NHS
England identified innovations where financial or procurement barriers were preventing
widespread adoption, despite strong evidence that broader adoption would deliver efficiency
and improve quality in healthcare. NHS England will provide reimbursement for usage of these
technologies through the ITP program to support their adoption throughout the NHS.
“We are delighted that NHS England has chosen to fund and to help encourage widespread
adoption of the HeartFlow Analysis as part of the ITP program,” said John H. Stevens, M.D.,
president and chief executive officer, HeartFlow. “We look forward to working with NHS England
to improve efficiency and the patient experience while delivering cost savings as demonstrated
in our clinical trials.”
The ITP designation for the HeartFlow Analysis follows medical technology guidance issued by
the National Institute for Health and Care Excellence (NICE) in February 2017, which
recommended the HeartFlow Analysis as the most cost-effective option following a coronary
computed tomography angiogram (CTA) when additional information is needed by the clinician
for patients with stable chest pain. Additionally, NICE clinical guidelines recommend coronary
CTA as the initial diagnostic test for most patients with stable chest pain.
“For patients being assessed in a chest pain clinic with new onset chest pain, the most
important focus is to first provide an accurate diagnosis as quickly as possible. It is ideal if we
can avoid unnecessary invasive procedures, like angiograms, or prevent having to do multiple
tests, one after the other. Most patients don't actually have angina and so being able to
reassure patients and avoid unnecessary tests is also really important,” said Dr. Andrew Wragg,
consultant cardiologist, Barts Heart Centre. “Using the HeartFlow Analysis at the Barts Heart
Centre helps us understand if a patient has a significant narrowing within their heart blood
vessels by assessing its impact on the actual blood flow to the heart muscle. This enables us to
make a more precise diagnosis and offer the most appropriate treatment. Many patients don’t
require any extra tests and can be reassured. Other patients can be correctly identified for more
invasive treatments. Also, the time to diagnosis is shorter and combined with avoiding
unnecessary tests, this can potentially lead to important cost savings for both the hospital and
wider healthcare system.”
About the HeartFlow FFRct Analysis
Clinicians diagnosing someone with suspected CAD want to know as definitively as possible if
the individual has a significant blockage in their coronary arteries. They also want to know the
impact of that blockage on blood flow so they can best determine which treatment pathway is
appropriate (e.g., medical management, stenting or coronary artery bypass grafting).
Data from a patient’s non-invasive coronary CTA are securely uploaded from the hospital’s
system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D
model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer
algorithms to solve millions of complex equations to simulate blood flow and assess the impact
of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure
online interface to offer actionable information to enable clinicians to determine the optimal
course of treatment. To date, clinicians around the world have used the HeartFlow Analysis for
more than 15,000 patients to aid in the diagnosis of heart disease.
This technology has been demonstrated to reduce unnecessary and invasive diagnostic
coronary angiography procedures, which can be associated with bleeding, stroke, major blood
vessel damage and other serious complications. It also significantly reduces healthcare costs
for hospitals.ii
About HeartFlow, Inc.
HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed
and treated. Our non-invasive HeartFlow FFRct Analysis leverages deep learning to create a
personalized 3D model of the heart. By using this model, clinicians can better evaluate the
impact a blockage has on blood flow and determine the best treatment for patients. Our
technology is reflective of our Silicon Valley roots and incorporates decades of scientific
evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is
commercially available in the United States, Canada, Europe and Japan. For more information,
visit www.heartflow.com.
# # #
Media Contact:
Jennie Kim
i British Heart Foundation. CVD Statistics Factsheet. February 2018. https://www.bhf.org.uk/research/heart-statistics
ii Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with
suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.
37460347 v1